"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
| Descriptor ID |
D007155
|
| MeSH Number(s) |
D27.505.696.477
|
| Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 2 | 7 |
| 1995 | 3 | 3 | 6 |
| 1996 | 3 | 1 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 2 | 4 |
| 2000 | 0 | 3 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 3 | 1 | 4 |
| 2003 | 1 | 4 | 5 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 1 | 2 |
| 2006 | 8 | 4 | 12 |
| 2007 | 9 | 9 | 18 |
| 2008 | 7 | 10 | 17 |
| 2009 | 6 | 7 | 13 |
| 2010 | 7 | 7 | 14 |
| 2011 | 9 | 9 | 18 |
| 2012 | 8 | 3 | 11 |
| 2013 | 8 | 12 | 20 |
| 2014 | 1 | 4 | 5 |
| 2015 | 4 | 6 | 10 |
| 2016 | 7 | 4 | 11 |
| 2017 | 8 | 8 | 16 |
| 2018 | 9 | 12 | 21 |
| 2019 | 12 | 12 | 24 |
| 2020 | 10 | 14 | 24 |
| 2021 | 4 | 19 | 23 |
| 2022 | 0 | 22 | 22 |
| 2023 | 0 | 6 | 6 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals. Front Immunol. 2024; 15:1348041.
-
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023 07 05; 29(13):2435-2444.
-
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 04; 29(4):869-879.
-
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology. 2023 09 01; 78(3):758-770.
-
To Combine or Not to Combine: Do We Need Concomitant Immunomodulators When Using Non-TNF-Targeting Biologics? Clin Gastroenterol Hepatol. 2023 10; 21(11):2743-2745.
-
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023 01 10; 7(1):9-19.
-
Modulating the tumor immune microenvironment with locoregional image-guided interventions. Front Immunol. 2022; 13:1057597.
-
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. Oncologist. 2022 Nov 03; 27(11):971-981.
-
Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. Dermatol Clin. 2023 Jan; 41(1):23-37.
-
Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions. Front Immunol. 2022; 13:1018202.